Connection

Maria Lopes-Virella to Antigen-Antibody Complex

Back to Details
This is a "connection" page, showing publications Maria Lopes-Virella has written about Antigen-Antibody Complex.
Maria Lopes-Virella
Connection Strength
7.189
Antigen-Antibody Complex
  1. Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1853-1860.
    View in: PubMed
    Score: 0.594
  2. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin Immunol. 2018 02; 187:1-9.
    View in: PubMed
    Score: 0.519
  3. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J Diabetes Complications. 2016 May-Jun; 30(4):693-9.
    View in: PubMed
    Score: 0.468
  4. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb. 2013; 20(10):743-54.
    View in: PubMed
    Score: 0.397
  5. Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem. 2013; 34(1):61-74.
    View in: PubMed
    Score: 0.380
  6. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012 Oct; 224(2):526-31.
    View in: PubMed
    Score: 0.370
  7. Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptors I and III. Clin Immunol. 2011 Jun; 139(3):258-66.
    View in: PubMed
    Score: 0.333
  8. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2011 Feb; 214(2):462-7.
    View in: PubMed
    Score: 0.328
  9. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011 Feb; 60(2):582-9.
    View in: PubMed
    Score: 0.326
  10. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008 Jun; 127(3):394-400.
    View in: PubMed
    Score: 0.276
  11. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis. 2009 Feb; 202(2):394-404.
    View in: PubMed
    Score: 0.276
  12. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006 Sep; 47(9):1975-83.
    View in: PubMed
    Score: 0.242
  13. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol. 2005 Jan; 12(1):68-75.
    View in: PubMed
    Score: 0.218
  14. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol. 2000 Dec; 20(12):2533-8.
    View in: PubMed
    Score: 0.164
  15. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000 Jun; 49(6):1033-41.
    View in: PubMed
    Score: 0.159
  16. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol. 1999 Jul; 19(7):1600-7.
    View in: PubMed
    Score: 0.149
  17. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999 Feb; 90(2):165-72.
    View in: PubMed
    Score: 0.145
  18. Association of apolipoprotein A phenotypes and oxidized low-density lipoprotein immune complexes in children. Arch Pediatr Adolesc Med. 1999 Jan; 153(1):57-62.
    View in: PubMed
    Score: 0.144
  19. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. 1997 Dec; 135(2):161-70.
    View in: PubMed
    Score: 0.133
  20. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol. 1997 Oct; 85(1):73-82.
    View in: PubMed
    Score: 0.132
  21. Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein. Clin Immunol Immunopathol. 1995 May; 75(2):179-89.
    View in: PubMed
    Score: 0.111
  22. Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes. J Lipid Res. 2014 May; 55(5):860-9.
    View in: PubMed
    Score: 0.103
  23. Lipoprotein-immune complexes and diabetic vascular complications. Diabetes. 1992 Oct; 41 Suppl 2:92-6.
    View in: PubMed
    Score: 0.093
  24. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb. 1991 Sep-Oct; 11(5):1356-67.
    View in: PubMed
    Score: 0.086
  25. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant. 2012 Apr; 27(4):1416-23.
    View in: PubMed
    Score: 0.086
  26. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One. 2010 Sep 02; 5(9).
    View in: PubMed
    Score: 0.081
  27. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82.
    View in: PubMed
    Score: 0.079
  28. Heat shock protein 70B' (HSP70B') expression and release in response to human oxidized low density lipoprotein immune complexes in macrophages. J Biol Chem. 2010 May 21; 285(21):15985-93.
    View in: PubMed
    Score: 0.078
  29. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010 Jan; 134(1):55-65.
    View in: PubMed
    Score: 0.074
  30. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007 Feb; 190(2):359-69.
    View in: PubMed
    Score: 0.059
  31. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins Other Lipid Mediat. 2006 Mar; 79(1-2):126-40.
    View in: PubMed
    Score: 0.059
  32. The immunogenicity of modified lipoproteins. Ann N Y Acad Sci. 2005 Jun; 1043:367-78.
    View in: PubMed
    Score: 0.056
  33. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004 Oct; 45(10):1859-67.
    View in: PubMed
    Score: 0.053
  34. Role of simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care. 2004 Apr; 27(4):908-13.
    View in: PubMed
    Score: 0.052
  35. Humoral immunity and atherosclerosis. Nat Med. 2003 Mar; 9(3):243-4; author reply 244-5.
    View in: PubMed
    Score: 0.048
  36. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002 Oct; 105(1):81-92.
    View in: PubMed
    Score: 0.047
  37. Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of FC gamma receptor II (FcgammaRII). Clin Immunol. 2002 Sep; 104(3):265-73.
    View in: PubMed
    Score: 0.046
  38. The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atherosclerosis. 2000 Sep; 152(1):107-15.
    View in: PubMed
    Score: 0.040
  39. Transcriptional and post-transcriptional regulation of LDL receptor gene expression in PMA-treated THP-1 cells by LDL-containing immune complexes. J Lipid Res. 1997 Jan; 38(1):110-20.
    View in: PubMed
    Score: 0.031
  40. Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes. 1996 Jul; 45 Suppl 3:S40-4.
    View in: PubMed
    Score: 0.030
  41. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes. 1992 Oct; 41 Suppl 2:86-91.
    View in: PubMed
    Score: 0.023
  42. Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin Immunol Immunopathol. 1991 Apr; 59(1):37-52.
    View in: PubMed
    Score: 0.021
  43. Immune mechanisms in the pathogenesis of atherosclerosis. Adv Exp Med Biol. 1991; 285:383-92.
    View in: PubMed
    Score: 0.021
  44. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med. 1988 Sep 01; 168(3):1041-59.
    View in: PubMed
    Score: 0.018
  45. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant. 2006 Jan; 21(1):93-100.
    View in: PubMed
    Score: 0.014
  46. Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. Immunology. 1983 Sep; 50(1):43-51.
    View in: PubMed
    Score: 0.012
  47. Soluble immune complexes in patients with diabetes mellitus: detection and pathological significance. Diabetologia. 1981 Sep; 21(3):184-91.
    View in: PubMed
    Score: 0.011
  48. Immunological and microbiological factors in the pathogenesis of atherosclerosis. Clin Immunol Immunopathol. 1985 Dec; 37(3):377-86.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.